A Phase II Study of Active Immunotherapy With PANVAC or Autologous Cultured Dendritic Cells Infected With PANVAC After Complete Resection of Hepatic or Pulmonary Metastases of Colorectal Carcinoma.

Trial Profile

A Phase II Study of Active Immunotherapy With PANVAC or Autologous Cultured Dendritic Cells Infected With PANVAC After Complete Resection of Hepatic or Pulmonary Metastases of Colorectal Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs CV 301 (Primary) ; CV 301 (Primary) ; Sargramostim
  • Indications Cancer metastases; Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 29 May 2013 Data have been published in the Annals of Surgery, according to a Bavarian Nordic media release.
    • 07 Nov 2012 Planned End Date changed from 1 Feb 2009 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top